Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities.
The program will compare postoperative outcomes (opioid utilization, length of stay, and patient-reported pain) between standard of care and procedures using VectorMist and The LASSO Protocol.
The parties have agreed to explore extending the same evidence architecture across Vector's broader portfolio, including its peptide therapeutics programs, subject to a separate agreement.
MEQUON, Wis. and SAN FRANCISCO, July 17, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector") and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist™, Vector's localized atomized drug delivery platform, and The LASSO Protocol™ (Laparoscopic Atomization System for Sparing Opioids).
VectorMist is designed to deliver atomized medication directly to the surgical site during laparoscopic procedures, providing targeted pain control at the source and reducing reliance on systemic opioids in postoperative recovery. The LASSO Protocol is the clinical protocol built on the VectorMist platform.
Under the agreement, Caresyntax will design and operate a multi-phase real-world evidence program across a network of partner surgical facilities. The program begins with baseline data collection on current standard-of-care procedures, capturing postoperative opioid utilization, length of stay, and patient-reported pain scores. A comparative phase then measures outcomes from VectorMist procedures against that baseline. The program culminates in a prospective comparative registry across the participating surgical network, giving institutions the ability to benchmark their outcomes against peer and cohort performance on a standardized data model.
The partnership positions VectorMist as a data-enabled surgical platform rather than a device-only offering. Every institution deploying VectorMist will contribute to and benefit from a growing body of real-world outcomes evidence, a value proposition aligned with the outcomes accountability that hospital purchasing committees and value-based care programs now require.
The parties have also agreed to explore extending the evidence architecture beyond VectorMist. Vector and Caresyntax intend to evaluate applying the same approach (standardized data capture, comparative analysis, and registry-based benchmarking) across Vector's broader portfolio, including its peptide therapeutics programs. A common evidence infrastructure would allow each program to draw on shared methodology, data governance, and clinical network rather than standing up parallel data efforts. Any such expansion would be subject to a separate agreement between the parties.